Home > COX & > Rofecoxib

Rofecoxib

罗非考昔,罗非昔布,MK0966,MK-0966,MK 0966

Rofecoxib是COX-2抑制剂，IC50为18nM。

目录号
EY1673
EY1673
纯度
99.66%
99.66%
规格
50 mg
100 mg
原价
290
480
售价
290
480
库存
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Rofecoxib is a COX-2 inhibitor with IC50 of 18 nM.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

    0.5 μM, 8 μM

  • 动物实验

    0.1 mg/kg/day，0.3 mg/kg/day，1.0 mg/kg/day，以及 3.0 mg/kg/day口服

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Chan CC, et al. J Pharmacol Exp Ther. 1999, 290(2), 551-560.

    分子式
    C17H14O4S    		 分子量
    314.36    		 CAS号
    162011-90-7    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    62 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT00038389 Glioma|Brain Neoplasms Drug: Vioxx M.D. Anderson Cancer Center Phase 1 2002-01-01 2012-07-27
    NCT00568295 Osteoarthritis of the Knee Drug: acetaminophen|Drug: Rofecoxib|Drug: Rofecoxib Johnson & Johnson Consumer and Personal Products Worldwide Phase 3 1999-10-01 2011-08-19
    NCT00060476 Prostate Cancer Drug: rofecoxib|Drug: Comparator: placebo (unspecified) Merck Sharp & Dohme Corp. Phase 3 2003-01-01 2015-09-15
    NCT00026819 Pain Drug: Rofecoxib National Institute of Dental and Craniofacial Research (NIDCR)|National Institutes of Health Clinical Center (CC) Phase 2 2001-11-01 2008-03-03
    NCT00050362 Pain|Tooth Extraction Drug: Rofecoxib and Bupivacaine National Institute of Dental and Craniofacial Research (NIDCR)|National Institutes of Health Clinical Center (CC) Phase 2 2002-12-01 2008-03-03
    NCT00657449 Acute Pain Drug: valdecoxib|Drug: rofecoxib Pfizer Phase 4 2003-06-01 2008-04-08
    NCT00031863 Colorectal Cancer Drug: rofecoxib|Procedure: adjuvant therapy Cancer Research Campaign Clinical Trials Centre|National Cancer Institute (NCI) Phase 3 2001-02-01 2013-08-01
    NCT00004845 Alzheimer Disease Drug: Rofecoxib|Drug: Naproxen National Institute on Aging (NIA)|Alzheimer's Disease Cooperative Study (ADCS) Phase 2|Phase 3 2009-12-10
    NCT00140894 Adenomatous Polyposis Coli Drug: MK0966; rofecoxib / Duration of Treatment: 24 weeks|Drug: Comparator: placebo / Duration of Treatment: 24 weeks Merck Sharp & Dohme Corp. Phase 4 2003-03-01 2006-11-30
    NCT00140933 Pain Drug: MK0966; rofecoxib|Drug: Comparator: diclofenac, placebo Merck Sharp & Dohme Corp. Phase 3 2003-04-01 2006-12-01
    NCT00157872 Rheumatoid Arthritis Drug: MK0966; rofecoxib|Drug: Comparator: naproxen tablet 500 mg Merck Sharp & Dohme Corp. Phase 4 2004-01-01 2015-06-17
    NCT01762891 Antiphospholipid Antibody Syndrome Drug: Celecoxib|Drug: Acetaminophen|Drug: Rofecoxib|Drug: placebo Hospital Universitario Pedro Ernesto 2003-03-01 2013-01-06
    NCT00140920 Pain Drug: MK0966; rofecoxib|Drug: Comparator: diclofenac 2x 75 mg Merck Sharp & Dohme Corp. Phase 4 2004-05-01 2015-06-01
    NCT00282386 Colorectal Adenoma Drug: MK0966; Rofecoxib / Duration of Treatment: 156 weeks|Drug: Placebo/ Duration of Treatment: 156 weeks Merck Sharp & Dohme Corp. Phase 3 1999-12-01 2015-09-15
    NCT00385606 Advanced Non-Small Cell Lung Cancer Drug: gemcitabine|Drug: prolonged continuous infusion gemcitabine|Drug: cisplatin|Drug: rofecoxib National Cancer Institute, Naples Phase 2|Phase 3 2003-01-01 2007-08-22
    NCT00637949 Osteoarthritis Device: lumiracoxib|Drug: rofecoxib Novartis Phase 3 2000-12-01 2008-03-17
    NCT00390260 Pain, Postoperative Arthroscopy Drug: MK0966 / Duration of Treatment: 1 Days|Drug: Comparator: acetaminophen (+) hydrocodone bitartrate / Duration of Treatment: 1 Days|Drug: Comparator: placebo (unspecified) / Duration of Treatment: 1 Days Merck Sharp & Dohme Corp. Phase 3 2002-02-01 2017-01-31
    NCT00637988 Barrett's Esophagus Drug: Esomeprazole|Drug: Aspirin|Drug: Rofecoxib AstraZeneca Phase 4 2002-04-01 2011-01-20
    NCT00263094 Headache Drug: Rofecoxib Sheba Medical Center 2004-09-01 2006-01-25
    NCT00092313 Postoperative Pain Drug: MK0966, rofecoxib|Drug: Comparator: oxycodone and acetaminophen Merck Sharp & Dohme Corp. Phase 3 2002-06-01 2015-11-24
    NCT00092339 Postoperative Pain Drug: MK0966, rofecoxib|Drug: Comparator: valdecoxib, placebo Merck Sharp & Dohme Corp. Phase 3 2002-08-01 2015-09-15
    NCT00092378 Postoperative Pain Drug: MK0966, rofecoxib|Drug: Comparator: diclofenac sodium, placebo Merck Sharp & Dohme Corp. Phase 3 2003-09-01 2015-04-09
    NCT00092300 Postoperative Pain Drug: MK0966, rofecoxib|Drug: Comparator: valdecoxib Merck Sharp & Dohme Corp. Phase 3 2002-05-01 2015-07-31
    NCT00092365 Osteoarthritis Drug: MK0966, rofecoxib|Drug: Comparator: celecoxib, placebo Merck Sharp & Dohme Corp. Phase 3 2003-04-01 2015-09-01
    NCT00092352 Osteoarthritis Drug: MK0966, rofecoxib|Drug: Comparator: celecoxib, placebo Merck Sharp & Dohme Corp. Phase 3 2003-04-01 2015-09-15
    NCT00092326 Postoperative Pain Drug: MK0966, rofecoxib|Drug: Comparator: oxycodone with acetaminophen, placebo Merck Sharp & Dohme Corp. Phase 3 2002-06-01 2016-02-19

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：